A2736
Anastrozole
≥98% (HPLC)
Sinônimo(s):
2;2"-[5-(1H-1;2;4-Triazol-1-ylmethyl)-1, 3-Phenylene]bis(2-methyl-propiononitrile, Arimidex, ICI-D1033, ZD1033, a,a,a′,a′-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Fórmula empírica (Notação de Hill):
C17H19N5
Número CAS:
Peso molecular:
293.37
Código UNSPSC:
51111800
NACRES:
NA.77
Produtos recomendados
Nível de qualidade
Ensaio
≥98% (HPLC)
Formulário
solid
solubilidade
DMSO: 40 mg/mL
originador
AstraZeneca
temperatura de armazenamento
room temp
InChI
1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3
chave InChI
YBBLVLTVTVSKRW-UHFFFAOYSA-N
Procurando produtos similares? Visita Guia de comparação de produtos
Aplicação
Anastrozole (aromatase inhibitor) has been used:
- as a positive control in DNA fragmentation (ladder) assay
- to investigate its effects along with extra virgin olive oil and its major fatty acid component (omega-9 OA) in estrogen receptor positive mammary adenocarcinoma cells
- to study its effects on viability, cell proliferation and apoptosis in Glioblastoma multiforme model in vivo
Ações bioquímicas/fisiológicas
Anastrozole, which contains a triazole functional group, reversibly binds to the cytochrome P-450 component of aromatase. Binding interferes with the catalytic properties of aromatase, which results in inhibition of estrogen synthesis.
The aromatase enzyme converts adrenal androgens to estrogen; this enzymatic activity is the primary source of estrogen production in postmenopausal women. One treatment for estrogen receptor-positive breast cancer in postmenopausal women is through inhibition of aromatase. Anastrozole is a nonsteroidal, benzyl-triazole derivative that inhibits aromatase through competitive inhibition and is used to treat estrogen receptor-positive breast cancer. This compound is considered a third-generation, Type II aromatase inhibitor because it is more selective and less effective (if at all) on other steroidal hormones than first and second generation inhibitors.
Características e benefícios
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Palavra indicadora
Danger
Frases de perigo
Declarações de precaução
Classificações de perigo
Acute Tox. 4 Oral - Repr. 1B
Código de classe de armazenamento
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Classe de risco de água (WGK)
WGK 3
Ponto de fulgor (°F)
Not applicable
Ponto de fulgor (°C)
Not applicable
Escolha uma das versões mais recentes:
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Os clientes também visualizaram
Novel acylated steroidal glycosides from Caralluma tuberculata induce caspase-dependent apoptosis in cancer cells
Waheed A, et al.
Journal of Ethnopharmacology, 137(3), 1189-1196 (2011)
Yanyan Hong et al.
Steroids, 76(8), 802-806 (2011-03-23)
Aromatase is the rate-limiting enzyme in estrogen biosynthesis. As a cytochrome P450, it utilizes electrons from NADPH-cytochrome P450 reductase (CPR) to produce estrogen from androgen. Estrogen is a key factor in the promotion of hormone-dependent breast cancer growth. Aromatase inhibitors
P Dubsky et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 24(3), 640-647 (2012-10-05)
In early estrogen receptor (ER)-positive/HER2-negative breast cancer, the decision to administer chemotherapy is largely based on prognostic criteria. The combined molecular/clinical EndoPredict test (EPclin) has been validated to accurately assess prognosis in this population. In this study, the clinical relevance
F Boccardo et al.
European journal of cancer (Oxford, England : 1990), 49(7), 1546-1554 (2013-02-19)
The Italian Tamoxifen Anastrozole (ITA) trial investigated the efficacy of switching to anastrozole for women who were already on adjuvant tamoxifen since 2-3years. Relapse-free survival (RFS) was the primary end-point; event-free survival (EFS), overall survival (OS) and safety were secondary
P I Petkov et al.
SAR and QSAR in environmental research, 20(7-8), 657-678 (2009-12-22)
Cytochrome P450 aromatase is a key steroidogenic enzyme that converts androgens to estrogens in vertebrates. There is much interest in aromatase inhibitors (AIs) both because of their use as pharmaceuticals in the treatment of estrogen-sensitive breast cancers, and because a
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica